Correlation Between HLA Allele and Drug Patch Test Result in Cutaneous Adverse Drug Reactions
Open Access
- 1 January 2026
- journal article
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Abstract
Background: Drug patch testing was affected by multiple influencing factors. HLA allele‐associated drug allergy was mentioned as one factor influencing drug patch testing. We aimed to evaluate the correlation between drug patch test and HLA alleles in patients with cutaneous adverse drug reactions. Methods: The study enrolled 30 patients, who had drug patch testing, to evaluate HLA alleles. We compared HLA alleles between patients with positive and negative patch test results and between those with positive patch tests and the Thai general population. Results: Among the 30 patients, including 20 positive patch test patients and 10 negative‐patch test patients, a distribution for males (50%) was observed, with a mean age of 55.4 ± 15.5. The most prevalent cutaneous drug reactions in patch test‐positive patients were morbilliform drug eruption 8/20 (40.0%) and fixed drug eruption 7/20 (35.0%). NSAIDs and antibiotics were the dominant culprit drug groups. These groups account for 5/20 (25.0%) and 4/20 (20.0%) of patients, respectively. None of the HLA alleles was significantly identified in patients with positive patch test compared to patients with negative patch test. However, HLA‐B ∗ 54:01 and HLA‐C ∗ 07:01 were significantly associated with patients who had positive patch test results for NSAID‐induced minor drug reactions when compared with the Thai general population ( p ≤ 0.0001), with odds ratios of 34 and 10, respectively. Conclusion: In this small pilot study, HLA‐B ∗ 54:01 and HLA‐C ∗ 07:01 alleles showed a preliminary association with positive patch test results in patients with NSAID‐induced minor drug reactions. We hypothesized that HLA alleles might influence the positive patch test reaction.Keywords
Funding Information
- Health Systems Research Institute (64-110)
- Health Systems Research Institute (67-088)
This publication has 23 references indexed in Scilit:
- Hydroxychloroquine-induced acute generalized exanthematous pustulosis with HLA-typingPharmacogenomics, 2024
- Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug ReactionsJAMA Dermatology, 2018
- Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactionsPharmacogenetics and Genomics, 2015
- Skin Testing in Delayed Reactions to DrugsImmunology and Allergy Clinics of North America, 2009
- HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patientsPharmacogenetics and Genomics, 2009
- HLA-B*5701 Screening for Hypersensitivity to AbacavirNew England Journal of Medicine, 2008
- HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinolProceedings of the National Academy of Sciences, 2005
- Guidelines for performing skin tests withdrugs in the investigation of cutaneous adverse drug reactionsContact Dermatitis, 2001
- Drug eruptions: a study including all inpatients and outpatients at a dermatology clinic of a university hospitalJournal of the European Academy of Dermatology and Venereology, 2000
- The use of skin testing in the investigation of cutaneous adverse drug reactionsBritish Journal of Dermatology, 1998